Evaluation of High Throughput Sequencing for Screening of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.

Overview

The study patients are patients suffering from primary or secondary immunodeficiencies investigated in the Hospital Necker for a suspected infectious disease. The study purpose is to assess the performance of a High Throughput Sequencing method, the PATHOQUEST method (from sample preparation to bio informatic analysis), versus the classic diagnostic approach. The study will evaluate the capacity of the PATHOQUEST method to detect pathogens responsible for an infectious disease episode and will also evaluate the delay of obtention of results compared to the classic diagnostic approach.

Full Title of Study: “Performance Assessment of High Throughput Sequencing for the Detection of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2014

Interventions

  • Procedure: Blood sampling / Body fluid sampling
    • During the hospitalization of the patient, when a sampling is done for classic follow-up and diagnosis, additionnal blood sampling will be done, for the PATHOQUEST method. Other body fluids might be taken (if the sampling is done for the classic follow-up), such as cerebrospinal fluid, ascite…

Arms, Groups and Cohorts

  • No study treatment

Clinical Trial Outcome Measures

Primary Measures

  • Identification of pathogens responsible for the infection
    • Time Frame: 1 year
    • The primary outcome will assess the number of diagnostics obtained by the PATHOQUEST method and classic diagnostic approach.

Secondary Measures

  • Delay of obtention of diagnostic
    • Time Frame: 1 year
    • The delay of obtention of results will be compared to determine which approach allows an earlier diagnosis.
  • Economic impact of the PATHOQUEST method
    • Time Frame: 1 year
    • Comparison of the cost of the classic diagnostic approach and PATHOQUEST method, including cost of the hospital stay, microbiological tests performed, empirical anti-infectious drugs prescribed.

Participating in This Clinical Trial

Summary of inclusion criteria:

1. Primary or secondary immunodeficiencies defined by

  • Solid organ transplantation and immunosuppressive drug – Recent chemotherapy – Hematopoïetic Stem Cells transplantation – Primary immune deficiency – Auto-immune disease – HIV infection 2. Infection suspicion 3. Microbiological investigation 4. Adult or child above 1 year 5. Hospitalization at Necker-Enfants malades hospital 6. Registration to Healthcare organism 7. ICF signature Summary of exclusion criteria:

1. Obvious diagnosis following clinical examination 2. Participation in a clinical trial for a new drug 3. People under legal guardianship 4. People unable to fulfil the required medical follow-up

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Pathoquest
  • Collaborator
    • Imagine Institute
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marc Lecuit, Pr, Principal Investigator, marc.lecuit@nck.aphp.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.